Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

European Cardiovascular Drugs Markets

Published by: Frost & Sullivan

Published: Oct. 1, 2006 - 149 Pages


Table of Contents


1. Executive Summary
        1. Overview
                  1. Overview of the European Cardiovascular Drugs Market
 
2. Glossary of Terms
        1. List of Terms
                  1. Abbreviations
 
3. Introduction
        1. Disease State Overview
                  1. Disease Description and Risk Factors
                  2. Types of Heart Disease
                  3. Disease Management and Current Treatments
        2. Research Methodology
                  1. Research Methodology for the European Cardiovascular Drugs Market
                  2. Assumptions and Limitations
 
4. Industry Challenges
        1. Challenges and Issues
                  1. Challenges Facing the European Cardiovascular Drugs Market
 
5. Market Engineering Research for World Cardiovascular Drugs Market
        1. World Cardiovascular Drugs Market
                  1. Introduction
                  2. Market Engineering Measurement Analysis
                  3. Revenue Forecasts
                  4. Trends by Geographic Regions
                  5. Segment Analysis
 
6. Market Engineering Research for European Cardiovascular Drugs Market
        1. European Cardiovascular Drugs Market
                  1. Introduction and Market Segmentation
                  2. Market Engineering Measurements Analysis
                  3. Key Market Drivers
                  a. Top Five European Companies Continue to Drive Market: Cardiovascular is Largest Segment
                  b. New Drug Areas, Classes, and Combination Products to Drive Future Growth Prospects
                  c. Increase in Diabetic and Obese Populations: Increases Risk of Chronic Disease
                  d. Aging Population: Drives Demand for New Drugs
                  e. Improved Technology: Increased Diagnosis
                  4. Key Market Restraints
                  a. Cost-containment to Lead to Price Pressures
                  b. Generic Competition: Impacting Revenues and Market Share of Major Brands
                  c. Shift in National Policies to Promote Prescription of Generic Drugs: Cut Costs
                  d. Specific Therapeutic Classes of Drugs are in Decline: Negative Growth Expected
                  5. Revenue Forecasts
                  6. Segment-wise Analysis
 
7. Cardiovascular Drugs Market in the United Kingdom
        1. Market Engineering Research
                  1. Market Overview
                  2. Revenue Forecasts
 
8. Cardiovascular Drugs Market in Germany
        1. Market Engineering Research
                  1. Market Overview
                  2. Revenue Forecasts
 
9. Cardiovascular Drugs Market in France
        1. Market Engineering Research
                  1. Market Overview
                  2. Revenue Forecasts
 
10. Cardiovascular Drugs Market in Italy
        1. Market Engineering Research
                  1. Market Overview
                  2. Revenue Forecasts
 
11. Cardiovascular Drugs Market in Spain
        1. Market Engineering Research
                  1. Market Overview
                  2. Revenue Forecasts
 
12. Portfolio Analysis
        1. Company Profiles and Product Pipeline
                  1. AstraZeneca
                  2. Bristol-Myers Squibb
                  3. Merck & Co. Inc
                  4. Novartis
                  5. Pfizer
                  6. Sanofi-Aventis
 
13. Strategic Recommendations
        1. Market Engineering Recommendations
                  1. Strategic Recommendations for the European Cardiovascular Drugs Market
 
14. Database of Key Industry Participants
        1. Key Industry Participants
                  1. Major Participants
 
15. Decision Support Databases
        1. Cardiovascular Diseases
                  1. Cardiovascular Prevalence
                  2. Percent of Cardiovascular Disease Prevalence
                  3. Prevalence of Hypertension
                  4. Prevalence of Hypertension as Percentage of Population
                  5. Incidence of Myocardial Infarction
                  6. Incidence of Stroke
                  7. Mortality due to Coronary Heart Disease
                  8. Mortality due to Circulatory Disease
                  9. Mortality due to Chronic Rheumatic Heart Disease
                  10. Heart Attack Mortality
                  11. Mortality due to Hypertensive Diseases



List of Figures

Chapter 4



  • Cardiovascular Drugs Market: Impact of Top Industry Challenges (Europe), 2006-2012


Chapter 5



  • Cardiovascular Drugs Market: Revenue Forecasts (World), 2002-2012

  • Cardiovascular Drugs Market: Revenue Forecasts (U.S.), 2002-2012

  • Cardiovascular Drugs Market: Revenue Forecasts (Japan), 2002-2012

  • Cardiovascular Drugs Market: Market Share by Geographic Regions (World), 2005

  • Cardiovascular Drugs Market: Market Share by Geographic Region (Europe), 2005

  • Cardiovascular Drugs Market: Breakdown by Segment (World), 2005

  • Cardiovascular Drugs Market: Breakdown by Segment (World), 2005


Chapter 6



  • Cardiovascular Drugs Market: Market Drivers Ranked in Order of Impact (Europe), 2006-2012

  • Cardiovascular Drugs Market: Market Restraints Ranked in Order of Impact (Europe), 2006-2012

  • Cardiovascular Drugs Market: Revenue Forecasts (Europe), 2002-2012

  • Cardiovascular Drugs Market: Breakdown by Segment (Europe), 2005

  • Cardiovascular Drugs Market: Breakdown by Segment (Europe), 2005


Chapter 7



  • Cardiovascular Drugs Market: Revenue Forecasts (U.K.), 2002-2012


Chapter 8



  • Cardiovascular Drugs Market: Revenue Forecasts (Germany), 2002-2012


Chapter 9



  • Cardiovascular Drugs Market: Revenue Forecasts (France), 2002-2012


Chapter 10



  • Cardiovascular Drugs Market: Revenue Forecasts (Italy), 2002-2012


Chapter 11



  • Cardiovascular Drugs Market: Revenue Forecasts (Spain), 2002-2012


Chapter 12



  • Cardiovascular Drugs Market: Product Sales of AstraZeneca (World), 2003-2005

  • Cardiovascular Drugs Market: Cardiovascular Pipeline of AstraZeneca (World), 2005

  • Cardiovascular Drugs Market: Discontinued Product Pipeline of AstraZeneca (World), 2005

  • Cardiovascular Drugs Market: Product Sales of Bristol-Myers Squibb (World), 2003-2005

  • Cardiovascular Drugs Market: Cardiovascular Pipeline of Bristol-Myers Squibb (World), 2005

  • Cardiovascular Drugs Market: Product Sales of Merck (World), 2003-2005

  • Cardiovascular Drugs Market: Cardiovascular Pipeline of Merck (World), 2005

  • Cardiovascular Drugs Market: Product Sales of Novartis (World), 2004-2005

  • Cardiovascular Drugs Market: Cardiovascular Pipeline of Novartis (World), 2005

  • Cardiovascular Drugs Market: Product Sales of Pfizer (World), 2003-2005

  • Cardiovascular Drugs Market: Cardiovascular Pipeline of Pfizer (World), 2005

  • Cardiovascular Drugs Market: Product Sales of Sanofi-Aventis (World), 2005

  • Cardiovascular Drugs Market: Cardiovascular Pipeline of Sanofi-Aventis (World), 2005


Chapter 13



  • Cardiovascular Drugs Market: Stages of Product Life Cycle and Strategy (Europe), 2005


Chapter 14



  • Cardiovascular Drugs Market: Database of Key Industry Participants (World), 2006


Chapter 15



  • Decision Support Database: Cardiovascular Prevalence in '000 (World), 1999-2006

  • Decision Support Database: Percent Cardiovascular Disease Prevalence (World), 1999-2006

  • Decision Support Database: Prevalence of Hypertension Million (World), 1999-2006

  • Decision Support Database: Prevalence of Hypertension as Percentage of Population (World), 1999-2006

  • Decision Support Database: Incidence of Myocardial Infarction (World), 1999-2006

  • Decision Support Database: Incidence of Stroke (World), 1999-2006

  • Decision Support Database: Mortality due to Coronary Heart Disease (World), 1999-2006

  • Decision Support Database: Circulatory Disease Mortality (World), 1999-2006

  • Decision Support Database: Mortality due to Chronic Rheumatic Heart Disease

  • (World), 1999-2006

  • Decision Support Database: Heart Attack Mortality (World), 1999-2006

  • Decision Support Database: Mortality due to Hypertensive Diseases (World), 1999-2006

Abstract

This research examines the European Cardiovascular Market in terms of the challenges faced by market participants, drivers and restraints in the industry, the competitive structure in the major markets, the revenue forecasts and growth rates and strategic recommendations.

Research Overview

This Frost & Sullivan research service entitled European Cardiovascular Drugs Market Analysis analyses the key industry challenges that cardiovascular companies are facing, as well as major drivers and restraints governing the market. It also offers strategic recommendations to overcome these challenges and ensure future growth and prospects. In this research service, Frost & Sullivan's expert analysts thoroughly examine the following segments of the European cardiovascular drugs market: antihypertensives, antidyslipidemics, antithrombotics and antiarrhythmics.

Market Overview

Patent Expiry a Huge Challenge for Pharmaceutical Companies

Seven of the world’s top 25 selling drugs are cardiovascular drugs, and of these, three are cholesterol-lowering agents. This clearly demonstrates the importance of the cardiovascular drugs market, which generates the maximum revenues in the overall pharmaceuticals industry. Within this market, antihypertensives form the largest segment due to sustained growth of angiotensin II receptor blockers (ARBs). Antidyslipidemics also have immense growth potential due to the growing number of people suffering from cholesterol, while antithrombotics have recorded the highest growth among the various segments in recent years due to the predominance of blockbuster drugs in this segment.

However, impending patent expiry on many best-selling drugs is a major challenge for pharmaceutical companies. Patent expiry on any one of a company’s blockbuster products is likely to impact its profit margins considerably. Loss of patents for a company that had focused on blockbuster drugs would reduce exclusivity and adversely affect its revenue growth, especially since cardiovascular drug sales account for nearly half of a company's annual revenue in some cases. "Pharmaceutical companies can adopt various key strategies to sustain growth such as using combination therapies to extend the life of the original product and adding value through drug delivery technologies," says the analyst of this research service. "They can also explore addressing unmet needs in the market to create new growth opportunities and add value through clinical differentiation."

Adding Value through Drug Discovery Technologies can Help Sustain Growth

With patent expiry posing a major threat to pharmaceutical companies, many of them have started using drug delivery technologies to give formulators a value-added opportunity to develop innovative, therapeutically enhanced alternatives. "By developing an enhanced version with therapeutic benefits such as improved efficacy, or dosing frequency or new therapeutic indications, patented drug companies can extend exclusivity," says the analyst. "This will allow them to compete more effectively against generics and branded products."

Ideally, companies need to examine drug delivery technologies as a potential way to add value much before patent expiry. They must develop enhanced products at least two to three years before loss of exclusivity if they wish to gain an edge in the market. By analysing the generic threat during the research phase itself, companies can formulate appropriate strategies and identify potential development partners that could help them maintain the post-patent value of products.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
  • Antihypertensives
  • Antidyslipidemics
  • Antithrombotics
  • Antiarrhythmics
Technologies

The following technologies are covered in this research:
  • Targeted molecular imaging
  • Magnetic resonance imaging (MRI)
  • Positron emission tomography (PET)


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008